Announcements - OBI Pharma 台灣浩鼎

2017.Jun.28

Important Resolutions of AGM 2017

2017.Jun.11

Supplemental information on the approved application of Phase III clinical trial of OBI-822, the novel breast cancer drug, in China, US, and the EU

2017.Jun.01

OBI Pharma Announces Acquisition of the Novel First-in-class Anti-Cancer Drug OBI-3424 from Threshold Pharmaceuticals to be Developed as Potential Anti-Cancer Therapy for Cancers with High AKR1C3

2017.Apr.26

Announcement of explanation on the first instance judgment of the civil action between the Company against "Next Magazine"

2017.Apr.17

Announcement of explanation on the Company's criminal lawsuit against Next Magazine

2017.Apr.06

OBI-833, the cancer therapeutic vaccine, has met the primary safety indicators in Phase I clinical trial for US and Taiwan

2017.Mar.09

The board of directors have resolved not to distribute dividends

2017.Mar.09

Announcement by the Company's Board of Directors to convene the 2016 Annual General Shareholders' meeting

2017.Mar.09

OBI Pharma’s Board of Directors approves the announcement of the Company’s 2016 individual and consolidated financial statements

2017.Jan.26

Supplemental Information: OBI-822 was approved to enter a Phase III clinical trial by the China Food and Drug Administration (CFDA)

News

Latest News

Events

Latest events